ArticleJTCVS techniques2026
In vitro construction of handmade polytetrafluoroethylene right ventricle-to-pulmonary artery valved conduit using a modification of the Ozaki technique.
Article in JTCVS techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a polytetrafluoroethylene (PTFE) valved conduit for right ventricle-to-pulmonary artery (RV-PA) reconstruction using a modified technique of the aortic neocuspidization described by Ozaki. Methods: Between June 2024 and September 2025, 12 patients underwent the placement of handmade PTFE valved RV-PA conduits. An inverted PTFE graft was marked for commissures and cusp nadirs. Three leaflets were fashioned from 0.1-mm PTFE membrane using Ozaki's sizer and template. Leaflets were sutured to the inner wall following the technique of Ozaki. Graft was then re-everted and commissures secured, ensuring symmetrical leaflet coaptation. Results: Median patient age was 12 years (interquartile range [IQR], 7, 15 years); male/female ratio was 7:5; median weight 25 kg (IQR, 17, 30 kg); and median body surface area was 0.9 (IQR, 0.7, 1.2). Diagnoses included double-outlet right ventricle ventricular septal defect pulmonary stenosis (n = 5), tetralogy of Fallot (TOF) (n = 2), post-Ross procedure (n = 2), TOF with subarterial ventricular septal defect (n = 1), atrioventricular canal defect with TOF (n = 1), and TOF postconduit (n = 1). Median peak preoperative right ventricular outflow tract gradient was 83 mm Hg (IQR, 77, 92 mm Hg). Median bypass time and clamp time were 173 minutes (IQR, 147, 218 minutes) and 137 minutes (IQR, 93, 162 minutes), respectively. Median conduit size was 19 mm (IQR, 16, 20 mm) versus expected PA annulus of 15 mm (IQR, 13.7, 16 mm). Median peak conduit gradient was 10 mm Hg (IQR, 3,16) immediately (n = 12), 10 mm Hg (IQR 3,17) at 1 month (n = 12), 10 mm Hg (IQR 3,18) at 3 months (n = 11), 12 mm Hg (IQR 5,18) at 6 months (n = 9), and 12 mm Hg (IQR 3,20) at 1 year (n = 7). Trivial, nonprogressive regurgitation was noted in 2 patients. Conclusions: This conduit is a simple, economical, and reproducible option for RV-PA reconstruction. It provides favorable early hemodynamic performance, demonstrating promise as a durable and accessible alternative to commercially available conduits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.